{"id":950779,"date":"2026-04-13T08:34:12","date_gmt":"2026-04-13T12:34:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/"},"modified":"2026-04-13T08:34:12","modified_gmt":"2026-04-13T12:34:12","slug":"alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/","title":{"rendered":"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong><br \/>\n          <em>&#8211; Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>SOUTH SAN FRANCISCO, Calif., April  13, 2026  (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology,\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026.<\/p>\n<p>\u201cJeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative therapies through critical stages of growth and advancing companies of our stage through late-stage development and commercialization,\u201d said Jason Lettmann, Chief Executive Officer at ALX Oncology. \u201cWe anticipate several important catalysts in the next 12 to 18 months with our evorpacept and ALX2004 clinical programs. Jeff\u2019s leadership will be instrumental in strengthening our development capabilities and operational infrastructure to support high-quality execution and deliver on these upcoming milestones.\u201d<\/p>\n<p>Mr. Knight brings more than 30 years of experience across the biopharmaceutical industry, with demonstrated success advancing programs from early development through commercialization, including multiple oncology programs. Most recently, he served as Chief Development and Operating Officer at Crinetics Pharmaceuticals, where he was responsible for clinical development, portfolio strategy, and corporate operations. Prior to joining Crinetics Pharmaceuticals, Mr. Knight held senior leadership roles at Poseida Therapeutics, Halozyme Therapeutics, Amgen and Onyx Pharmaceuticals, where he led development and operational functions within these organizations. Earlier in his career, he held several roles at Genentech, gaining extensive experience in oncology clinical development and regulatory affairs.<\/p>\n<p>\u201cALX Oncology is entering a critical phase of growth, with multiple opportunities to advance its pipeline and build a scalable organization,\u201d said Mr. Knight.\u00a0\u201cI am incredibly excited about ALX\u2019s clinical programs and data and look forward to working with the team to ensure strategic development and operational excellence as the company advances toward key clinical and corporate milestones.\u201d<\/p>\n<p>Mr. Knight holds a Master of Public Health in Biostatistics and Epidemiology and a Bachelor of Arts in Psychology from the University of Oklahoma, as well as a Bachelor of Science in Nursing from the University of Kansas.\u00a0<\/p>\n<p>\n        <strong>About ALX Oncology<\/strong><br \/>\n        <br \/>ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology\u2019s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N6Ng9S9nKK8auk2GxJ2w2cHrpqHr-1G4XsPomR0Zaxdp2YLTcNwYwAkWTPFhqeMmaCYEvfGezoJ4U5QlTuIcb8pySl4Fzed4ZGcd6FR5ySw=\" rel=\"nofollow\" target=\"_blank\">www.alxoncology.com<\/a> and on LinkedIn @<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nnIGZ_9mrOv6eqt4thrOdm89io0Y34pcc-IIrbdXT7976x6f27TiGUhI7IfcvxxMoZ6vsngnDSCDaXM2ZtGdm3kOt-5t7oWOUHIEkUDEXcay-RKnbahVm6OFNBs_q_sx\" rel=\"nofollow\" target=\"_blank\">ALX Oncology<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology\u2019s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology\u2019s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology\u2019s filings with the Securities and Exchange Commission (SEC), including ALX Oncology\u2019s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>\n        <strong>Investor Relations Contact: <\/strong><br \/>\n        <br \/>Elhan Webb, CFA, IR Consultant<br \/>ewebb@alxoncology.com<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Michele Parisi, SparkPoint Healthcare Communications<br \/>mparisi@sparkpointpr.com<br \/>(925) 864-5028<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjE5MTUyYjYtYTE5Mi00NzFkLWFjNjItOWIzNTk0M2Q5YjYxLTEyMDQ0MTYtMjAyNi0wNC0xMy1lbg==\/tiny\/ALX-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology,\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. \u201cJeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative therapies through critical stages of growth and advancing companies of our stage through late-stage development and commercialization,\u201d said Jason Lettmann, Chief Executive Officer at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-950779","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology,\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. \u201cJeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative therapies through critical stages of growth and advancing companies of our stage through late-stage development and commercialization,\u201d said Jason Lettmann, Chief Executive Officer at &hellip; Continue reading &quot;ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:34:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer\",\"datePublished\":\"2026-04-13T12:34:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/\"},\"wordCount\":716,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/\",\"name\":\"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=\",\"datePublished\":\"2026-04-13T12:34:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Market Newsdesk","og_description":"&#8211; Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology,\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. \u201cJeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative therapies through critical stages of growth and advancing companies of our stage through late-stage development and commercialization,\u201d said Jason Lettmann, Chief Executive Officer at &hellip; Continue reading \"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-13T12:34:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer","datePublished":"2026-04-13T12:34:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/"},"wordCount":716,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/","name":"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=","datePublished":"2026-04-13T12:34:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4Nzk3MSM3NTMwMzUxIzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=950779"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950779\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=950779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=950779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=950779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}